The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
From 1996-2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting ...
The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning ...
A promising new treatment accelerates myelin repair, potentially restoring vision and improving brain function in people with ...
Researchers at the University of Colorado Anschutz Medical Campus have identified LL-341070, a promising drug candidate that ...
The FDA is adding a new boxed warning to include information that anaphylaxis can occur at any time, from as early as after ...
Jan 22 (Reuters) - The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of some multiple sclerosis drugs including Teva's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback